$87.7 Million is the total value of Asymmetry Capital Management, L.P.'s 38 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Sell | PTC THERAPEUTICS | $8,644,000 | -6.0% | 319,444 | -42.1% | 10.81% | -13.4% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS | $4,727,000 | -21.9% | 31,304 | -30.4% | 5.91% | -28.1% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $3,749,000 | -16.7% | 17,518 | -14.2% | 4.69% | -23.2% |
| DGX | Sell | QUEST DIAGNOSTICS | $3,233,000 | -48.4% | 32,229 | -49.3% | 4.04% | -52.4% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $2,929,000 | -4.6% | 194,745 | -8.7% | 3.66% | -12.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $2,158,000 | -10.0% | 29,133 | -32.4% | 2.70% | -17.1% |
| HRTX | Sell | HERON THERAPEUTICS | $2,135,000 | +18.9% | 77,346 | -22.0% | 2.67% | +9.6% |
| DRRX | Sell | DURECT CORPORATION | $1,611,000 | +98.9% | 752,767 | -14.3% | 2.02% | +83.3% |
| TCMD | Sell | TACTILE SYSTEMS TECHNOLOGY INC | $1,350,000 | +8.2% | 42,460 | -1.5% | 1.69% | -0.3% |
| NVRO | Sell | NEVRO CORP | $1,134,000 | -30.9% | 13,087 | -45.0% | 1.42% | -36.4% |
| BIO | Sell | BIO-RAD LABRATORIES | $1,128,000 | -65.7% | 4,511 | -67.3% | 1.41% | -68.4% |
| PRGO | Sell | PERRIGO CO PLC | $1,062,000 | -32.8% | 12,747 | -29.7% | 1.33% | -38.1% |
| PRTO | Exit | PROTEON THERAPEUTICS INC | $0 | – | -9,400 | -100.0% | -0.02% | – |
| SNNAQ | Exit | SIENNA BIOPHARMACEUTICALS | $0 | – | -26,692 | -100.0% | -0.66% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -25,311 | -100.0% | -1.16% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -10,733 | -100.0% | -1.30% | – |
| ALDR | Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -92,518 | -100.0% | -1.44% | – |
| SGYPQ | Exit | SYNERGY PHARMACEUTICALS INC | $0 | – | -477,621 | -100.0% | -1.44% | – |
| TEVA | Exit | TEVA PHARMACEUTICALadr | $0 | – | -69,124 | -100.0% | -1.78% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -216,687 | -100.0% | -2.67% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.